Abstract
MicroRNAs (miRNAs) are a class of post-transcriptional gene expression modulators. In the past two decades, over 1500 human miRNAs were discovered. These small non-coding RNAs regulate various biological processes, including cell growth, proliferation, differentiation, and cell death. Thus, miRNAs have been proposed as new therapeutical agents in different multifactorial diseases such as cancer. Since miRNAs therapies represent a great promise, many research studies have been focused on the development of delivery strategies to overcome miRNAs biopharmaceutical issues. Lipid delivery systems are undoubtedly the non-viral carriers most largely investigated due to their biocompatibility, biodegradability, easy production, low toxicity and immunogenicity, possibility to easily modify the carriers for targeting strategies. In this mini-review we provide a rapid and updated overview on the lipid delivery system currently used to deliver miRNAs, pointing out the progresses achieved in the optimization of these nanovectors, which led up to the first clinical trial.
Keywords: microRNAs; miRNA delivery, nanocarriers; lipid-based delivery systems; liposomes, SNALPs, solid lipid nanoparticles, nanoemulsions, drug targeting.
Current Pharmaceutical Biotechnology
Title:Lipid Nanoparticles to Deliver miRNA in Cancer
Volume: 17 Issue: 8
Author(s): Virginia Campani, Giuseppe De Rosa, Gabriella Misso, Mayra R. Zarone and Anna Grimaldi
Affiliation:
Keywords: microRNAs; miRNA delivery, nanocarriers; lipid-based delivery systems; liposomes, SNALPs, solid lipid nanoparticles, nanoemulsions, drug targeting.
Abstract: MicroRNAs (miRNAs) are a class of post-transcriptional gene expression modulators. In the past two decades, over 1500 human miRNAs were discovered. These small non-coding RNAs regulate various biological processes, including cell growth, proliferation, differentiation, and cell death. Thus, miRNAs have been proposed as new therapeutical agents in different multifactorial diseases such as cancer. Since miRNAs therapies represent a great promise, many research studies have been focused on the development of delivery strategies to overcome miRNAs biopharmaceutical issues. Lipid delivery systems are undoubtedly the non-viral carriers most largely investigated due to their biocompatibility, biodegradability, easy production, low toxicity and immunogenicity, possibility to easily modify the carriers for targeting strategies. In this mini-review we provide a rapid and updated overview on the lipid delivery system currently used to deliver miRNAs, pointing out the progresses achieved in the optimization of these nanovectors, which led up to the first clinical trial.
Export Options
About this article
Cite this article as:
Campani Virginia, De Rosa Giuseppe, Misso Gabriella, R. Zarone Mayra and Grimaldi Anna, Lipid Nanoparticles to Deliver miRNA in Cancer, Current Pharmaceutical Biotechnology 2016; 17 (8) . https://dx.doi.org/10.2174/138920101708160517234941
DOI https://dx.doi.org/10.2174/138920101708160517234941 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assessment of miR-212 and Other Biomarkers in the Diagnosis and Treatment of HBV-infection-related Liver Diseases
Current Drug Metabolism Takotsubo Cardiomyopathy
Current Pharmaceutical Design Tc-99m Radiolabeled Alendronate Sodium Microemulsion: Characterization and Permeability Studies Across Caco-2 Cells
Current Drug Delivery Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets An Evolving Role of Piperazine Moieties in Drug Design and Discovery
Mini-Reviews in Medicinal Chemistry Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p
Current Molecular Pharmacology Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Current Signal Transduction Therapy Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Targeting Tumor Angiogenesis in Gastrointestinal Malignancies
Current Angiogenesis (Discontinued) Targeted Therapies in Lung Cancer
Current Pharmaceutical Design Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets From TGF-β to Cancer Therapy
Current Drug Targets Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry The Role of Apoptosis in Tumor Progression and Metastasis
Current Molecular Medicine